DiaSorin Strikes Dx Partnership With MeMed To Address Antibiotic Overuse
First licensing agreement for MeMed adds its immune system-based protein signature test to DiaSorin’s LIAISON test menu.
You may also be interested in...
MeMed has received CE Marking for its diagnostic test MeMed BV and point-of-need platform MeMed Key, which uses the human immune system to distinguish between bacterial and viral infections to prevent antibiotic overuse.
Israeli company MeMed has developed a proprietary diagnostic platform which uses proprietary immune system biomarkers to rapidly distinguish between viral and bacterial infections. The firm already has a CE -marked lab-based product, ImmunoXpert, which has been validated in three studies, the last of that trilogy having just published results confirming the test's ability to accurately distinguish between bacterial and viral infections.
The Dutch start-up will use the funds to finalize product design for a neurostimulation platform targeting chronic migraines.